NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses

被引:649
作者
Watanabe, T
Kitani, A
Murray, PJ
Strober, W
机构
[1] NIAID, Mucosal Immun Sect, Host Def Lab, NIH, Bethesda, MD 20892 USA
[2] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA
关键词
D O I
10.1038/ni1092
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The mechanism by which mutations in CARD15, which encodes nucleotide-binding oligomerization domain 2 (NOD2), cause Crohn disease is poorly understood. Because signaling via mutated NOD2 proteins leads to defective activation of the transcription factor NF-kappaB, one proposal is that mutations cause deficient NF-kappaB-dependent T helper type 1 (T(H)1) responses and increased susceptibility to infection. However, this idea is inconsistent with the increased T(H)1 responses characteristic of Crohn disease. Here we used Card15(-/-) mice to show that intact NOD2 signaling inhibited Toll-like receptor 2-driven activation of NFkappaB, particularly of the NF-kappaB subunit c-Rel. Moreover, NOD2 deficiency or the presence of a Crohn disease-like Card15 mutation increased Toll-like receptor 2-mediated activation of NF-kappaB-c-Rel, and T(H)1 responses were enhanced. Thus, CARD15 mutations may lead to disease by causing excessive T(H)1 responses.
引用
收藏
页码:800 / 808
页数:9
相关论文
共 50 条
  • [1] Toll-like receptor signaling
    Akira, S
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (40) : 38105 - 38108
  • [2] Toll-like receptors: critical proteins linking innate and acquired immunity
    Akira, S
    Takeda, K
    Kaisho, T
    [J]. NATURE IMMUNOLOGY, 2001, 2 (08) : 675 - 680
  • [3] Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan
    Bonen, DK
    Ogura, Y
    Nicolae, DL
    Inohara, N
    Saab, L
    Tanabe, T
    Chen, FF
    Foster, SJ
    Duerr, RH
    Brant, SR
    Cho, JH
    Nuñez, G
    [J]. GASTROENTEROLOGY, 2003, 124 (01) : 140 - 146
  • [4] The immunological and genetic basis of inflammatory bowel disease
    Bouma, G
    Strober, W
    [J]. NATURE REVIEWS IMMUNOLOGY, 2003, 3 (07) : 521 - 533
  • [5] Distinct roles for the NF-κB1 (p50) and c-Rel transcription factors in inflammatory arthritis
    Campbell, IK
    Gerondakis, S
    O'Donnell, K
    Wicks, IP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (12) : 1799 - 1806
  • [6] Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing toll-like receptors
    Cario, E
    Rosenberg, IM
    Brandwein, SL
    Beck, PL
    Reinecker, HC
    Podolsky, DK
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 164 (02) : 966 - 972
  • [7] Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases
    Chamaillard, M
    Philpott, D
    Girardin, SE
    Zouali, H
    Lesage, S
    Chareyre, F
    Bui, TH
    Giovannini, M
    Zaehringer, U
    Penard-Lacronique, V
    Sansonetti, PJ
    Hugot, JP
    Thomas, G
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (06) : 3455 - 3460
  • [8] Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945
  • [9] Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation
    Chamaillard, M
    Girardin, SE
    Viala, J
    Philpott, DJ
    [J]. CELLULAR MICROBIOLOGY, 2003, 5 (09) : 581 - 592
  • [10] The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease
    Cuthbert, AP
    Fisher, SA
    Mirza, MM
    King, K
    Hampe, J
    Croucher, PJP
    Mascheretti, S
    Sanderson, J
    Forbes, A
    Mansfield, J
    Schreiber, S
    Lewis, CM
    Mathew, CG
    [J]. GASTROENTEROLOGY, 2002, 122 (04) : 867 - 874